L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release
Status:
Completed
Trial end date:
2019-03-20
Target enrollment:
Participant gender:
Summary
The gut is able to retain some fat for many hours after a fatty meal. The gut hormone
glucagon-like peptide-2 (GLP-2) is known to release these fat stores in the gut, but it is
not known how GLP-2 achieves this. One possibility is that GLP-2 increases blood flow in the
gut. NG-monomethyl-L-arginine (L-NMMA) is a substance that inhibits nitric oxide synthase (an
enzyme that helps make nitric oxide which increases blood flow). This protocol examines
whether blocking gut blood flow with L-NMMA is able to prevent GLP-2 from releasing gut lipid
stores. Healthy participants will be treated with a combination of Teduglutide (a resistant
form of GLP-2) and L-NMMA, and their respective controls. Blood lipid levels will be measured
following treatments.